Drug Profile
Research programme: microRNA-targeted therapeutics - Rosetta Genomics
Alternative Names: miR-34a therapeutics - Rosetta/Weizmann InstituteLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Rosetta Genomics
- Developer Rosetta Genomics; Weizmann Institute of Science
- Class Antisense oligonucleotides
- Mechanism of Action RNA inhibitors; Tumour suppressor protein p53 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Israel (Parenteral)
- 06 Feb 2017 Rosetta Genomics receives patent allowance for hsa-miR-146-5p and hsa-miR-551b-3p for the treatment of Cancer in USA
- 23 Sep 2015 Rosetta Genomics receives patent allowance for anti-hsa-miR-210 for the treatment of Prostate cancer in USA